HC Wainwright Weighs in on Biomea Fusion Q1 Earnings

Biomea Fusion, Inc. (NASDAQ:BMEA) – Equities research analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Biomea Fusion in a research report issued to clients and investors on Tuesday, April 1st. HC Wainwright analyst J. Pantginis forecasts that the company will earn ($0.85) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $40.00 target price on the stock. The consensus estimate for Biomea Fusion’s current full-year earnings is ($3.93) per share. HC Wainwright also issued estimates for Biomea Fusion’s Q2 2025 earnings at ($0.91) EPS, Q3 2025 earnings at ($1.03) EPS and Q4 2025 earnings at ($1.11) EPS.

Several other research analysts have also commented on BMEA. Barclays decreased their price objective on shares of Biomea Fusion from $11.00 to $3.00 and set an “equal weight” rating for the company in a report on Wednesday. D. Boral Capital reissued a “buy” rating and issued a $16.00 price target on shares of Biomea Fusion in a research note on Wednesday, March 19th. Finally, Oppenheimer set a $10.00 price objective on Biomea Fusion in a research report on Monday, March 24th. Two equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $23.91.

Biomea Fusion Stock Up 8.5 %

Shares of Biomea Fusion stock opened at $2.16 on Wednesday. The company has a market cap of $78.28 million, a PE ratio of -0.54 and a beta of -0.26. The business has a 50 day moving average of $3.19 and a 200 day moving average of $5.89. Biomea Fusion has a 52 week low of $1.87 and a 52 week high of $14.43.

Biomea Fusion (NASDAQ:BMEA) last released its quarterly earnings results on Monday, March 31st. The company reported ($0.81) EPS for the quarter, beating analysts’ consensus estimates of ($1.00) by $0.19.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Wellington Management Group LLP bought a new stake in shares of Biomea Fusion in the 4th quarter worth $317,000. Wexford Capital LP boosted its position in shares of Biomea Fusion by 2.3% during the fourth quarter. Wexford Capital LP now owns 133,343 shares of the company’s stock valued at $517,000 after buying an additional 3,007 shares during the last quarter. Two Sigma Advisers LP increased its holdings in Biomea Fusion by 290.7% in the 4th quarter. Two Sigma Advisers LP now owns 459,500 shares of the company’s stock worth $1,783,000 after buying an additional 341,900 shares in the last quarter. Two Sigma Investments LP raised its position in Biomea Fusion by 104.4% in the 4th quarter. Two Sigma Investments LP now owns 559,930 shares of the company’s stock worth $2,173,000 after buying an additional 286,049 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. purchased a new position in Biomea Fusion in the 4th quarter worth about $766,000. 96.72% of the stock is owned by hedge funds and other institutional investors.

Biomea Fusion Company Profile

Biomea Fusion, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes.